Show simple item record Soares, Esmeralda Augusta Jardim Machado Santos, André Felipe Andrade dos Sousa, Thatiana de Melo e Sprinz, Eduardo Martinez, Ana Maria Barral de Bastos, Jussara Silveira Tanuri, Amilcar Soares, Marcelo Alves 2012-09-03T18:26:07Z 2012-09-03T18:26:07Z 2007
dc.identifier.citation SOARES, Esmeralda Augusta Jardim Machado et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. Plos One, v. 2, n. 8, p. 01-08, 2007. Disponível em: <>. Acesso em: 30 ago. 2012. pt_BR
dc.description.abstract Background. Subtype C is the most prevalent HIV-1 subtype in the world, mainly in countries with the highest HIV prevalence. However, few studies have evaluated the impact of antiretroviral therapy on this subtype. In southern Brazil, the first developing country to offer free and universal treatment, subtypes B and C co-circulate with equal prevalence, allowing for an extensive evaluation of this issue. Methods and Findings. Viral RNA of 160 HIV-1+ patients was extracted, and the protease and reverse transcriptase genes were sequenced, subtyped and analyzed for ARV mutations. Sequences were grouped by subtype, and matched to type (PI, NRTI and NNRTI) and time of ARV exposure. Statistical analyses were performed to compare differences in the frequency of ARV-associated mutations. There were no significant differences in time of treatment between subtypes B and C groups, although they showed distinct proportions of resistant strains at different intervals for two of three ARV classes. For PI, 26% of subtype B strains were resistant, compared to only 8% in subtype C (p = 0.0288, Fisher’s exact test). For NRTI, 54% of subtype B strains were resistant versus 23% of subtype C (p = 0.0012). Differences were significant from 4 years of exposure, and remained so until the last time point analyzed. The differences observed between both subtypes were independent of time under rebound viremia in cases of virologic failure and of the number of HAART regimens used by treated patients. Conclusions. Our results pointed out to a lower rate of accumulation of mutations conferring resistance to ARV in subtype C than in subtype B. These findings are of crucial importance for current initiatives of ARV therapy roll-out in developing countries, where subtype is C prevalent. pt_BR
dc.language.iso eng pt_BR
dc.rights open access pt_BR
dc.title Differential drug resistance acquisition in HIV-1 of subtypes B and C pt_BR
dc.type article pt_BR
dc.identifier.doi 10.1371/journal.pone.0000730 pt_BR

Files in this item

This item appears in the following Collection(s)


  • FAMED – Artigos publicados em periódicos
  • Show simple item record